Literature DB >> 2386902

Survival of patients with ovarian cancer. Apart from stage and grade, tumor progesterone receptor content is a prognostic indicator.

B J Slotman1, J J Nauta, B R Rao.   

Abstract

Estrogen (ER), progesterone (PR), and androgen receptors (AR) were determined by saturation analysis in 100 cases of primary ovarian cancer and correlated with patient survival. The mean follow-up period was 5.4 years (range, 4 to 6.5 years). Positivity for PR was associated with a significantly better survival rate (P less than 0.05). A similar observation was made for AR (P less than 0.05). Tumor ER content did not correlate with survival. Ten patients with tumors that had negative results for both PR and AR all died of the disease. In 91 cases of serous, endometrioid, and mucinous carcinomas, grade, stage, and tumor PR content, but not AR content, were identified as independent prognostic factors with the use of the Cox proportional hazards model. The relative risk of patients with PR-negative tumors was 2.3 times higher than that of patients with tumors containing high (greater than or equal to 30 fmol/mg) PR levels.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2386902     DOI: 10.1002/1097-0142(19900815)66:4<740::aid-cncr2820660423>3.0.co;2-h

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  No association of a 306-bp insertion polymorphism in the progesterone receptor gene with ovarian and breast cancer.

Authors:  T P Manolitsas; P Englefield; D M Eccles; I G Campbell
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

2.  Immunohistochemical analysis of p53 protein and 72 kDa heat shock protein (HSP72) expression in ovarian carcinomas. Correlation with clinicopathology and sex steroid receptor status.

Authors:  M Koshiyama; I Konishi; M Mandai; T Komatsu; S Yamamoto; K Nanbu; T Mori
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

3.  Highly and moderately aggressive mouse ovarian cancer cell lines exhibit differential gene expression.

Authors:  Fengkun Du; Yan Li; Wensheng Zhang; Shubha P Kale; Harris McFerrin; Ian Davenport; Guangdi Wang; Elena Skripnikova; Xiao-Lin Li; Nathan J Bowen; Leticia B McDaniels; Yuan-Xiang Meng; Paula Polk; Yong-Yu Liu; Qian-Jin Zhang
Journal:  Tumour Biol       Date:  2016-03-02

4.  Cathepsin D immunoreactivity in ovarian cancer: correlation with prognostic factors.

Authors:  P Athanassiadou; V Sakellariou; E Petrakakou; P Athanassiades; C Zerva; A Liossi; S Michalas
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

5.  Survival of women with ovarian carcinomas and borderline tumors is not affected by estrogen and progesterone receptor status.

Authors:  Luis Felipe Sallum; Luis Otavio Sarian; Liliana Lucci De Angelo Andrade; José Vassallo; Fernando Augusto Soares; Glauce Aparecida Pinto; Patrícia Andréia Ferreira; Sophie Derchain
Journal:  J Gynecol Oncol       Date:  2013-04-05       Impact factor: 4.401

Review 6.  Prognostic value of progesterone receptor expression in ovarian cancer: a meta-analysis.

Authors:  Hui Luo; Saisai Li; Menghuang Zhao; Bo Sheng; Haiyan Zhu; Xueqiong Zhu
Journal:  Oncotarget       Date:  2017-05-30

7.  Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy.

Authors:  G Scambia; P Benedetti-Panici; G Ferrandina; M Distefano; G Salerno; M E Romanini; A Fagotti; S Mancuso
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

8.  A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma.

Authors:  N J McKenna; D G Kieback; D N Carney; M Fanning; J McLinden; D R Headon
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

9.  Prognostic impact of chromosome aberrations in ovarian cancer.

Authors:  T Pejovic; A Himmelmann; S Heim; N Mandahl; U M Flodérus; S Furgyik; B Elmfors; G Helm; H Willén; F Mitelman
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.